Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine

References

• American Cancer Society. Key Statistics About Liver Cancer. Available from: https://www.cancer.org/cancer/types/liver-cancer/about/what-is-key-statistics.html. Accessed December 12, 2023.
   Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Younis MA, Khalil IA, Abd Elwakil MM, Harashima H. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Mol Pharmaceut. 2019;16(9):4031–4044.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Goto R, Watanabe M, Kawamura N, Takada Y. Liver Transplantation for Hepatocellular Carcinoma: how Should We Improve the Thresholds? Cancers. 2022;14(2):419.
   PubMed Web of Science ®Google Scholar
• Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp. Mol. Med. 2022;54(10):1670–1694.
   PubMed Web of Science ®Google Scholar
• FDA. KYMRIAH (tisagenlecleucel). Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed December 12, 2023.
   Google Scholar
• therapeutics S. LUXTURNA (voretigene neparvovec-rzyl). Available from: https://luxturna.com/. Accessed December 12, 2023.
   Google Scholar
• Younis MA, Khalil IA, Harashima H. Gene Therapy for Hepatocellular Carcinoma: highlighting the Journey from Theory to Clinical Applications. Advanced Tharapeutics. 2020;3(11):2000087.
   Web of Science ®Google Scholar
• Abdellatif AAH, Younis MA, Alsowinea AF, et al. Lipid nanoparticles technology in vaccines: shaping the future of prophylactic medicine. Colloids Surf. B. 2023;222:113111.
   PubMed Web of Science ®Google Scholar
• The Nobel Prize. The Nobel Prize in Chemistry 2020. Available from: https://www.nobelprize.org/prizes/chemistry/2020/press-release/. Accessed December 12, 2023.
   Google Scholar
• The Nobel Prize. The Nobel Prize in Physiology or Medicine; 2023. Available from: https://www.nobelprize.org/prizes/medicine/2023/summary/. Accessed December 12, 2023.
   Google Scholar
• Dimri M, Satyanarayana A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers. 2020;12(2):567.
   PubMed Web of Science ®Google Scholar
• Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Can Cell Inter. 2021;21(1):208.
   PubMed Web of Science ®Google Scholar
• Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: diagnosis, Prognosis and Treatment Response Assessment. Cells. 2020;9(6).
   Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58.
   PubMed Web of Science ®Google Scholar
• Vanova T, Konecna Z, Zbonakova Z, et al. Tyrosine Kinase Expressed in Hepatocellular Carcinoma, TEC, Controls Pluripotency and Early Cell Fate Decisions of Human Pluripotent Stem Cells via Regulation of Fibroblast Growth Factor-2 Secretion. Stem Cells (Dayton, Ohio). 2017;35(9):2050–2059.
   PubMed Web of Science ®Google Scholar
• Shinde SD, Sahu B, Chamoli A, Mandoli A, Kalia K, Behera SK. Chapter 9 - Tyrosine kinases: their role in hepatocellular carcinoma. In: Nagaraju GP, Vadde R, editors. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2. Academic Press; 2022:133–148.
   Google Scholar
• da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis. 2020;24(4):719–737.
   PubMed Web of Science ®Google Scholar
• Moawad AW, Szklaruk J, Lall C, et al. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma. 2020;7:77–89.
   PubMed Web of Science ®Google Scholar
• Bielenberg DR, Zetter BR. The Contribution of Angiogenesis to the Process of Metastasis. Cancer j. 2015;21(4):267–273.
   PubMed Web of Science ®Google Scholar
• West H, Jin JO. Transarterial Chemoembolization. JAMA Oncol. 2015;1(8):1178–1178.
   PubMed Web of Science ®Google Scholar
• Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci. 2021;22(23):13051.
   PubMed Web of Science ®Google Scholar
• Nilsson M, Heymach JV. Vascular Endothelial Growth Factor (VEGF) Pathway. J Thorac Oncol. 2006;1(8):768–770.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: a Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1097–1105.
   PubMedGoogle Scholar
• Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(3):912–920.
   PubMed Web of Science ®Google Scholar
• Matsui D, Nagai H, Mukozu T, Ogino Y, Sumino Y. VEGF in Patients with Advanced Hepatocellular Carcinoma Receiving Intra-arterial Chemotherapy. Anticancer Res. 2015;35(4):2205–2210.
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005;1:2005.0010.
   PubMed Web of Science ®Google Scholar
• Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 2021;13(11):758.
   PubMed Web of Science ®Google Scholar
• Huang P, Xu X, Wang L, Zhu B, Wang X, Xia J. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell & Mol Med. 2014;18(2):218–230.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–6663.
   PubMed Web of Science ®Google Scholar
• Koch I, Baron A, Roberts S, et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2005;23(16_suppl).
   Web of Science ®Google Scholar
• Choi K-J, Baik IH, S-K Y, Lee Y-H. Molecular Targeted Therapy for Hepatocellular Carcinoma: present Status and Future Directions. Biol. Pharm. Bull. 2015;38(7):986–991.
   PubMed Web of Science ®Google Scholar
• Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci. 2020;10(1):41.
   PubMed Web of Science ®Google Scholar
• Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene. 2005;24(11):1809–1819.
   PubMed Web of Science ®Google Scholar
• Liu J, Ahiekpor A, Li L, et al. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int j Cancer. 2009;125(8):1894–1901.
   PubMed Web of Science ®Google Scholar
• Daveau M, Scotte M, François A, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinogenesis. 2003;36(3):130–141.
   PubMed Web of Science ®Google Scholar
• Berasain C, Ujue Latasa M, Urtasun R, et al. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers. 2011;3(2):2444–2461.
   PubMedGoogle Scholar
• Chen Z, Jiang L, Liang L, et al. The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma. Am J Pathol. 2021;191(7):1180–1192.
   PubMed Web of Science ®Google Scholar
• Alvarez-Sola G, Uriarte I, Latasa MU, et al. Engineered fibroblast growth factor 19 protects from Acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis. 2017;8(10):e3083.
   PubMedGoogle Scholar
• Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002;160(6):2295–2307.
   PubMed Web of Science ®Google Scholar
• Yun YR, Won JE, Jeon E, et al. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng. 2010;2010:218142.
   PubMedGoogle Scholar
• Liu J, Fan L, Yu H, et al. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology. 2019;70(1):241–258.
   PubMed Web of Science ®Google Scholar
• Miyata M, Hata T, Yamazoe Y, Yoshinari K. SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells. Biochem. Biophys. Res. Commun. 2014;443(2):477–482.
   PubMed Web of Science ®Google Scholar
• Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641–2653.
   PubMed Web of Science ®Google Scholar
• Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51(6):1976–1980.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–3516.
   PubMed Web of Science ®Google Scholar
• Hagel M, Miduturu C, Sheets M, et al. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discovery. 2015;5(4):424–437.
   PubMed Web of Science ®Google Scholar
• Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45(4):319–326.
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–1312.
   PubMed Web of Science ®Google Scholar
• Liu CH, Chern GJ, Hsu FF, et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology. 2018;67(3):899–913.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Singh S, Poddar M, et al. Hepatic Stellate Cell-Specific Platelet-Derived Growth Factor Receptor-α Loss Reduces Fibrosis and Promotes Repair after Hepatocellular Injury. Am J Pathol. 2020;190(10):2080–2094.
   PubMed Web of Science ®Google Scholar
• Yu JH, Kim JM, Kim JK, et al. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget. 2017;8(24):39534–39546.
   PubMedGoogle Scholar
• Younis MA, Sato Y, Elewa YHA, Kon Y, Harashima H. Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis. J Controlled Release. 2023;353:685–698.
   PubMed Web of Science ®Google Scholar
• Younis MA, Sato Y, Elewa YHA, Harashima H. Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice. J Controlled Release. 2023;361:592–603.
   PubMed Web of Science ®Google Scholar
• Uhrbom L, Hesselager G, Nistér M, Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998;58(23):5275–5279.
   PubMed Web of Science ®Google Scholar
• Östman A. PDGF receptors in tumor stroma: biological effects and associations with prognosis and response to treatment. Adv. Drug Delivery Rev. 2017;121:117–123.
   PubMed Web of Science ®Google Scholar
• Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest. 2004;84(6):766–777.
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14(3):285–294.
   PubMedGoogle Scholar
• Qin Y, Rezler EM, Gokhale V, Sun D, Hurley LH. Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4. Nucleic Acids Res. 2007;35(22):7698–7713.
   PubMed Web of Science ®Google Scholar
• Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta haematologica. 1996;95(3–4).
   PubMed Web of Science ®Google Scholar
• Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619–1649.
   PubMed Web of Science ®Google Scholar
• Wang W, Shui L, Liu Y, Zheng M. C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases. Front Genetics. 2021;12:598855.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dai X, Wang T, et al. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett. 2017;400:149–160.
   PubMed Web of Science ®Google Scholar
• Kwon YC, Bose SK, Steele R, et al. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol. 2015;89(22):11549–11556.
   PubMed Web of Science ®Google Scholar
• Cai X, Zhai J, Kaplan DE, et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology. 2012;56(5):1804–1816.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45.
   PubMedGoogle Scholar
• You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011;54(3):879–889.
   PubMed Web of Science ®Google Scholar
• Wang H, Rao B, Lou J, et al. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Develop Biol. 2020;8:55.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA. 2003;100(22):12718–12723.
   PubMed Web of Science ®Google Scholar
• Crosswell HE, Dasgupta A, Alvarado CS, et al. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009;9(1):411.
   PubMedGoogle Scholar
• Hong DS, LoRusso P, Hamid O, et al. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019;25(8):2403–2413.
   PubMed Web of Science ®Google Scholar
• Zhang S-Z, Pan F-Y, J-F X, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2005;4(10):1577–1584.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang H, Ning T, et al. Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer. Int j nanomed. 2020;15(null).
   Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866–3884.
   PubMed Web of Science ®Google Scholar
• Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–1983.
   PubMed Web of Science ®Google Scholar
• Xu Z, Hu J, Cao H, et al. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp. Mol. Med. 2018;50(1):e417–e417.
   PubMedGoogle Scholar
• Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113(12):1774–1783.
   PubMed Web of Science ®Google Scholar
• Yan X, Huang S, Yang Y, et al. Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis. Liver transplantation. 2022;28(6):1063–1077.
   PubMed Web of Science ®Google Scholar
• Grabinski N, Ewald F, Hofmann BT, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012;11:85.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib: the EVOLVE-1 Randomized Clinical Trial. JAMA. 2014;312(1):57–67.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Joseph NM, Nimeiri HS, et al. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer. 2021;10(6):561–571.
   PubMed Web of Science ®Google Scholar
• Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma. Tumour Biol. 2020;42(4):1010428320914475.
   Google Scholar
• Mok WC, Wasser S, Tan T, Lim SG. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2012;18(27):3527–3536.
   PubMed Web of Science ®Google Scholar
• El Dika I, Lim HY, Yong WP, et al. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Oncologist. 2019;24(6):747–e218.
   PubMed Web of Science ®Google Scholar
• Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.
   PubMed Web of Science ®Google Scholar
• Feng DY, Zheng H, Tan Y, Cheng RX. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol. 2001;7(1):33–36.
   PubMed Web of Science ®Google Scholar
• Ghousein A, Mosca N, Cartier F, et al. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation. Liver Int. 2020;40(1):240–251.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–1047.
   PubMed Web of Science ®Google Scholar
• Hennig M, Yip-Schneider MT, Wentz S, et al. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology. 2010;51(4):1218–1225.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Tian H. Current Development Status of MEK Inhibitors. Molecules (Basel, Switzerland). 2017;22(10).
   Web of Science ®Google Scholar
• Liu Y, Tan M, Zhang Y, et al. Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem. Nanoscale Res Lett. 2020;15(1):116.
   PubMed Web of Science ®Google Scholar
• Bessard A, Frémin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene. 2008;27(40):5315–5325.
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Li YX, Jayaraman A, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 2006;27(4):748–757.
   PubMed Web of Science ®Google Scholar
• Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1(2):83–93.
   PubMed Web of Science ®Google Scholar
• Li Y, Pu S, Liu Q, et al. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Controlled Release. 2019;303:77–90.
   PubMed Web of Science ®Google Scholar
• Li J, Cai H, Li H, et al. Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer. Oncol Rep. 2019;41(3):1991–1997.
   PubMed Web of Science ®Google Scholar
• Huang XH, Chen JS, Wang Q, et al. miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J pathol. 2011;225(3):463–472.
   PubMed Web of Science ®Google Scholar
• Hu X, li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction Targeted Therapy. 2021;6(1):402.
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous Activation of emRas and Jak/Stat Pathways in Human HCC. Gastroenterology. 2006;130(4):1117–1128.
   PubMed Web of Science ®Google Scholar
• Mohan CD, Bharathkumar H, Bulusu KC, et al. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. J Biol Chem. 2014;289(49):34296–34307.
   PubMed Web of Science ®Google Scholar
• Wang XH, Liu BR, Qu B, et al. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma. 2011;58(2):158–171.
   PubMed Web of Science ®Google Scholar
• Cavalcante RS, Ishikawa U, Silva ES, et al. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. Br. J. Pharmacol. 2021;178(11):2284–2304.
   PubMed Web of Science ®Google Scholar
• Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proce Japan Acad. 2010;86(4):410–425.
   Google Scholar
• Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040–2054.
   PubMed Web of Science ®Google Scholar
• Younis MA, Khalil IA, Elewa YHA, Kon Y, Harashima H. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. J Controlled Release. 2021;331:335–349.
   PubMed Web of Science ®Google Scholar
• Wang J, Tai G. Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development. Targeted Oncol. 2016;11(6):723–738.
   PubMed Web of Science ®Google Scholar
• Kuntzen C, Sonuc N, De Toni EN, et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res. 2005;65(15):6780–6788.
   PubMed Web of Science ®Google Scholar
• Yu Q, Liu Z-Y, Chen Q, J-s L. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma. J Huazhong Univ Sci Technol. 2016;36(4):494–500.
   PubMedGoogle Scholar
• Wirth T, Kuhnel F, Fleischmann-Mundt B, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res. 2005;65(16):7393–7402.
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu LB, Yue XJ, Yu XH, Wang J, Liu C. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil. Oncol Rep. 2013;29(3):967–974.
   PubMed Web of Science ®Google Scholar
• Robinson K, Tiriveedhi V. Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Front Oncol. 2020;10:265.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Gholami MH, Hashemi F, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today. 2022;27(2):436–455.
   PubMed Web of Science ®Google Scholar
• Yang H, Ding R, Tong Z, et al. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma. Anticancer Res. 2016;36(6):2675–2682.
   PubMed Web of Science ®Google Scholar
• Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precision Oncol. 2018;2(1):6.
   PubMedGoogle Scholar
• Mazzocca A, Dituri F, De Santis F, et al. Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma. Cancer Res. 2015;75(3):532–543.
   PubMed Web of Science ®Google Scholar
• Syed V. TGF-β Signaling in Cancer. J Cell Biochem. 2016;117(6):1279–1287.
   PubMed Web of Science ®Google Scholar
• Lu DMEPY, Inventor. Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer. 2020.
   Google Scholar
• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773–1796.
   PubMed Web of Science ®Google Scholar
• Shen B, Zhang G, Liu Y, Wang J, Jiang J. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma. Genes. 2022;13(10).
   Web of Science ®Google Scholar
• Xu D, Tian Y, Xia Q, Ke B. The cGAS-STING Pathway: novel Perspectives in Liver Diseases. Front Immunol. 2021;12:682736.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release. 2015;216:149–157.
   PubMed Web of Science ®Google Scholar
• Khalifa AM, Nakamura T, Sato Y, et al. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. Int J Pharm. 2022;624:122034.
   PubMedGoogle Scholar
• Shobaki N, Sato Y, Suzuki Y, Okabe N, Harashima H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J Controlled Release. 2020;325:235–248.
   PubMed Web of Science ®Google Scholar
• Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression. 2020;20(1):53–65.
   PubMed Web of Science ®Google Scholar
• Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.
   PubMedGoogle Scholar
• Chen P, Li Y, Wei P, et al. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma. Int Immunopharmacol. 2022;111:109127.
   PubMed Web of Science ®Google Scholar
• Hombach S, Kretz M. Non-coding RNAs: classification, Biology and Functioning. In: Slaby O, Calin GA, editors. Non-Coding RNAs in Colorectal Cancer. Cham: Springer International Publishing; 2016:3–17.
   Google Scholar
• Abdellatif AAH, Scagnetti G, Younis MA, et al. Non-coding RNA-directed therapeutics in lung cancer: delivery technologies and clinical applications. Colloids Surf. B. 2023;229:113466.
   PubMed Web of Science ®Google Scholar
• Gulìa C, Baldassarra S, Signore F, et al. Role of Non-Coding RNAs in the Etiology of Bladder Cancer. Genes. 2017;8(11):339.
   PubMed Web of Science ®Google Scholar
• Wong C-M, Tsang FH-C, IO-L N. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(3):137–151.
   PubMed Web of Science ®Google Scholar
• Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget. 2016;7(1):241–254.
   PubMedGoogle Scholar
• Li SP, Xu HX, Yu Y, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016;7(27):42431–42446.
   PubMed Web of Science ®Google Scholar
• Fu WM, Zhu X, Wang WM, et al. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling. J Hepatol. 2015;63(4):886–895.
   PubMed Web of Science ®Google Scholar
• Lin YH, Liao CJ, Huang YH, et al. Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells. Oncogene. 2013;32(38):4509–4518.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun W, Shen W, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol. 2016;64(6):1283–1294.
   PubMed Web of Science ®Google Scholar
• Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(3):137–151.
   PubMed Web of Science ®Google Scholar
• Li CH, Xu F, Chow S, et al. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. Eur. J. Cancer. 2014;50(15):2560–2569.
   PubMed Web of Science ®Google Scholar
• Wong QW, Ching AK, Chan AW, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res. 2010;16(3):867–875.
   PubMed Web of Science ®Google Scholar
• Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol. 2010;12(4):390–399.
   PubMed Web of Science ®Google Scholar
• Li L, Tang J, Zhang B, et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64(1):156–167.
   PubMed Web of Science ®Google Scholar
• Huang MD, Chen WM, Qi FZ, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50.
   PubMed Web of Science ®Google Scholar
• Huang JL, Ren TY, Cao SW, et al. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget. 2015;6(32):33791–33804.
   PubMedGoogle Scholar
• Zhu P, Wang Y, Huang G, et al. lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016;23(7):631–639.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Tang J, et al. LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death Dis. 2016;7(3):e2130.
   PubMedGoogle Scholar
• Han H, Du Y, Zhao W, et al. PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells. Nat Commun. 2015;6:8271.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhao N, Li S, et al. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 2013;58(2):642–653.
   PubMed Web of Science ®Google Scholar
• Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19(2):232–243.
   PubMed Web of Science ®Google Scholar
• Chai S, Tong M, Ng KY, et al. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014;5(14):5725–5735.
   PubMedGoogle Scholar
• Wang TH, Lin YS, Chen Y, et al. Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. Oncotarget. 2015;6(27):23342–23357.
   PubMedGoogle Scholar
• Liu F, Yuan JH, Huang JF, et al. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene. 2016;35(41):5422–5434.
   PubMed Web of Science ®Google Scholar
• Chen CL, Tseng YW, Wu JC, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. Biomaterials. 2015;44:71–81.
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu S, Ye F, et al. Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma Cells. PLoS One. 2015;10(10):e0139790.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Younis MA, Kimura S, Harashima H. Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids. Biol. Pharm. Bull. 2020;43(4):584–595.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato Y, Yamada Y, et al. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv. Drug Delivery Rev. 2022;188:114417.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, S-p H. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduction Targeted Therapy. 2020;5(1):101.
   PubMed Web of Science ®Google Scholar
• Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 2008;49(6):977–984.
   PubMed Web of Science ®Google Scholar
• Deng Z, Yang H, Tian Y, Liu Z, Sun F, Yang P. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol. 2022;12:975408.
   PubMedGoogle Scholar
• Hernández-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. Ann. Hepatol. 2007;6(1):5–14.
   PubMed Web of Science ®Google Scholar
• Wang X, Tang Y, Lu J, et al. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochem. Pharmacol. 2016;105:80–90.
   PubMed Web of Science ®Google Scholar
• Niu Y, Lin Z, Wan A, et al. Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. Hepatology. 2021;74(3):1461–1479.
   PubMed Web of Science ®Google Scholar
• Wan Y, Ge K, Zhou W, Lu J, Jia C, Zhu H. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1). Biol. Chem. 2021;402(6):729–737.
   PubMed Web of Science ®Google Scholar
• Yu S, Zhao R, Zhang B, et al. Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma. Asian J. Pharm. Sci. 2023;18(4):100828.
   PubMed Web of Science ®Google Scholar
• Kazemian P, Yu S-Y, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Mol Pharmaceut. 2022;19(6):1669–1686.
   PubMed Web of Science ®Google Scholar
• O’Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004;6(6):611–623.
   PubMed Web of Science ®Google Scholar
• Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 2003;9(2):693–702.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol therapy. 2002;5(5 Pt 1).
   PubMed Web of Science ®Google Scholar
• Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003;63(12):3181–3188.
   PubMed Web of Science ®Google Scholar
• Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Therapy. 2004;9(4):496–509.
   PubMed Web of Science ®Google Scholar
• Martin NT, Crupi MJF, Taha Z, et al. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy. Pharmaceuticals. 2023;16(5):709.
   Web of Science ®Google Scholar
• Adu-Berchie K, Brockman JM, Liu Y, et al. Adoptive T cell transfer and host antigen-presenting cell recruitment with cryogel scaffolds promotes long-term protection against solid tumors. Nat Commun. 2023;14(1):3546.
   PubMed Web of Science ®Google Scholar
• X-A L. A clinical research of CAR T cells targeting EpCAM positive cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03013712. Accessed December 12, 2023.
   Google Scholar
• Finn RS. A phase I open label clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRs specific for alpha fetoprotein (AFPc331T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC). Available from: https://clinicaltrials.gov/ct2/show/NCT03132792. Accessed December 12, 2023.
   Google Scholar
• Peron JM, Couderc B, Rochaix P, et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenterol Hepatol. 2004;19(4):388–396.
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001;61(9):3725–3734.
   PubMed Web of Science ®Google Scholar
• Vollmer CM, Eilber FC, Butterfield LH, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999;59(13):3064–3067.
   PubMed Web of Science ®Google Scholar
• Younis MA, Tawfeek HM, Abdellatif AAH, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv. Drug Delivery Rev. 2022;181:114083.
   PubMedGoogle Scholar
• Grimm CF, Ortmann D, Mohr L, et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology. 2000;119(4):1104–1112.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823).
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chang Z, Lu M, et al. Shape-controlled magnetic mesoporous silica nanoparticles for magnetically-mediated suicide gene therapy of hepatocellular carcinoma. Biomaterials. 2018;154:147–157.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca. Accessed December 12, 2023.
   Google Scholar
• Younis MA. Chapter 17 - Clinical translation of silver nanoparticles into the market. In: Kesharwani P, editor. Silver Nanoparticles for Drug Delivery. Academic Press; 2024:395–432.
   Google Scholar
• Abdellatif AAH, Younis MA, Alsharidah M, Al Rugaie O, Tawfeek HM. Biomedical Applications of Quantum Dots: overview, Challenges, and Clinical Potential. Int J Nanomed. 2022;17:1951–1970.
   PubMed Web of Science ®Google Scholar